ClinicalTrials.Veeva

Menu

Characterization of Endothelial Dysfunction as a Function of Hyperaemia of the Brachial Artery During Cardiac Surgery (GLYNO)

C

Centre Hospitalier Universitaire, Amiens

Status

Unknown

Conditions

Capillary Leak Syndrome

Treatments

Biological: plasma

Study type

Observational

Funder types

Other

Identifiers

NCT02853682
PI2015_843_0027

Details and patient eligibility

About

The glycocalyx is a layer of proteins and complex sugars covering the endothelium of vessels. Its role as capillary filtration control is important. In case of alteration of the glycocalyx, experimental models and some clinical studies show an increased capillary leak responsible for interstitial edema. The analysis of glycocalyx in routine care is important to guide volume expansion. Indeed, the literature provides evidence about the poor prognosis of excess water and its impact on organ. This analysis challenge is to justify filling solution of choice according to the characteristic of this capillary leakage.

Full description

Extra corporeal circulation and aortic clamp induce ischemia-reperfusion damages.

Vascular damages are represented by first glycocalyx, a layer of endovascular vessel proteoglycans, responsible for fluid permeability and secondly by nitro oxygen liberation responsible for vascular tonus.

The investigators suppose that both functions are impaired after cardiac surgery.

Enrollment

28 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • cardiac surgery

Exclusion criteria

  • auricular fibrillation
  • endocarditis
  • aortic dissection
  • end stage chronic renal disease

Trial design

28 participants in 2 patient groups

presence of a vascular dysfunction
Description:
plasma
Treatment:
Biological: plasma
absence of vascular dysfunction
Description:
plasma
Treatment:
Biological: plasma

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems